Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

520
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
520
Tumor Immunotherapy01:27

Tumor Immunotherapy

675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nano-micro Combination: Overcoming Dual Intranasal Barriers to Elicit a Comprehensive Immune Response.

ACS applied materials & interfaces·2026
Same author

Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma.

ACS nano·2026
Same author

Fabrication of Tissue Constructs and Organoids Using Electrospun Micro/Nanofibers.

Chemical reviews·2026
Same author

"AND" Logic-Gated Biomimetic Nanoparticles to Activate Macrophage Phagocytosis for Cancer Immunotherapy.

Nano letters·2026
Same author

High-Performance Flexible Pyroelectric Energy Harvesting System Enabled by Light-Driven Thermomechanical Coupling in Liquid Crystal Elastomer.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Multiferroic Orders and Piezoelectric Sensing in an Organic-Inorganic Bismuth Halide.

Angewandte Chemie (International ed. in English)·2026

Related Experiment Video

Updated: Sep 19, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K

Resiquimod-Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy.

Wei Xu1,2, Jia-Qi Luo1, Shi-Yu Wang3

  • 1Laboratory of Smart Nanomedicines, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510006, China.

Angewandte Chemie (International Ed. in English)
|June 18, 2025
PubMed
Summary

This study introduces a novel nanovaccine using resiquimod (R848) conjugated to a dendrimer carrier. This innovative cancer immunotherapy approach demonstrates significant prophylactic and therapeutic effects, offering personalized treatment potential.

Keywords:
Cytosolic antigen deliveryNanovaccinePersonalized cancer immunotherapyPolyamidoamineResiquimod

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

813
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.3K

Related Experiment Videos

Last Updated: Sep 19, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

813
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.3K

Area of Science:

  • Biotechnology
  • Immunology
  • Materials Science

Background:

  • Cancer nanovaccines show promise for immunotherapy but face challenges in structural complexity and immune activation timing.
  • Optimizing nanovaccine design is crucial for enhancing therapeutic efficacy against tumors.

Purpose of the Study:

  • To develop a resiquimod-induced nanovaccine (RINV) for personalized cancer immunotherapy.
  • To create a nanovaccine carrier (G5-R848) for improved antigen delivery and immune response.

Main Methods:

  • Covalent conjugation of Toll-like receptor (TLR) 7/8 agonist resiquimod (R848) to a fifth-generation polyamidoamine (G5-PAMAM) dendrimer via a disulfide linker.
  • Formation of nanovaccines by complexing G5-R848 with model antigen ovalbumin (OVA) or tumor cell lysates.
  • Evaluation of in vivo prophylactic and therapeutic effects in a B16F10-OVA melanoma model.

Main Results:

  • The G5-R848 nanovaccine facilitated uniform formation with antigens and enabled redox-triggered intracellular release of R848.
  • Demonstrated significant prophylactic and therapeutic anti-tumor effects in a melanoma mouse model.
  • Personalized nanovaccines formed with tumor cell lysates effectively inhibited postoperative tumor recurrence and metastasis.

Conclusions:

  • The developed resiquimod-induced nanovaccine (RINV) offers a promising strategy for personalized cancer immunotherapy.
  • This nanovaccine design enhances antigen cross-presentation and elicits robust anti-tumor immune responses.
  • The approach shows potential for preventing postoperative tumor recurrence and metastasis.